Randomized phase 2 study of perampanel for sporadic amyotrophic lateral sclerosis.

Hitoshi AizawaHaruhisa KatoKoji ObaTakuya KawaharaYoshihiko OkuboTomoko SaitoMakiko NaitoMakoto UrushitaniAkira TamaokaKiyotaka NakamagoeKazuhiro IshiiTakashi KandaMasahisa KatsunoNaoki AtsutaYasushi MaedaMakiko NagaiKazutoshi NishiyamaHiroyuki IshiuraTatsushi TodaAkihiro KawataKoji AbeIchiro YabeIkuko Takahashi-IwataHidenao SasakiHitoshi WaritaMasashi AokiGen SobueHidehiro MizusawaYutaka MatsuyamaTomohiro HagaShin Kwak

Published in: Journal of neurology (2021)

Perampanel was associated with a significant decline in ALSFRS-R score and was linked to worsening of the bulbar subscore in the 8 mg group.

Keyphrases

amyotrophic lateral sclerosis
open label
double blind
placebo controlled
phase iii
phase ii
clinical trial
study protocol
randomized controlled trial
early onset